組合技術
有一種放大抗體治療效能的方法,就是將其結合或「複合」成小分子藥物,這些小分子藥物可同時將藥物及抗體鎖定特定抗原的能力組合起來,使得這種複合藥物的潛在療效得以發揮.[5] 另一種提高抗體治療潛能的方法,就是使用可產生雙特異性抗體來鎖定兩種抗原(也稱為雙重可變結構域抗體)的技術.[6]
[1]Turanli-Yildiz B, Alkim C, Cakar ZP. Protein Engineering Methods and Applications. Protein Engineering. 2012;ISBN 9789535100379:33-58. Source
[2]Discovery of small molecule cancer drugs: Successes, challenges and opportunities, Mol Oncol, Aprio 2012;6(2):155-176.
[3]Alberts, B., Johnson, A., Lewis, J., Morgan, D., Raff, M., Roberts, K., & Walter, P. (2015). Cell death, Molecular biology of the cell (6th ed.). (pp. 1021-1034). New York, NY: Garland Science.
[4]National Cancer Institute FactSheet, Biological Therapies for Cancer: http://www.cancer.gov/cancertopics/factsheet/Therapy/biological , accessed April 29, 2014.
[5]Sassoon I, Blanc V. Antibody-drug conjugate (ADC) clinical pipeline: a review. Methods Mol Biol. 2013;1045:1-27.
[6]Eigenbrot, C. & Fuh, G. Two-in-One antibodies with dual action Fabs. Current Opinion in Chemical Biology. 2013; 17: 400-405.